COMMUNIQUÉS West-GlobeNewswire

Foamix Reports First Quarter 2018 Financial Results and Provides Corporate Update

08/05/2018 - 23:04

Conference Call and Webcast on Wednesday, May 9 at 8:30am Eastern Time REHOVOT, Israel, May 08, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX ) (“Foamix” or the “Company”), a clinical stage [...]

Reata Pharmaceuticals, Inc. Announces First Quarter 2018 Financial Results and an Update on Development Programs

08/05/2018 - 23:00

CATALYST TRIAL IN CTD-PAH FINAL SAMPLE SIZE SET AT 200; TOP-LINE DATA EXPECTED IN THE FIRST HALF OF 2020 PHOENIX TRIAL INTERIM DATA FOR ADPKD AND IGA NEPHROPATHY COHORTS AT ERA-EDTA IN MAY; FULL DATA FOR THESE COHORTS [...]

Pacific Biosciences Announces Favorable Outcome in UK and German Patent Litigation Against Oxford Nanopore

08/05/2018 - 23:00

MENLO PARK, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB ), the leader in long-read, high-resolution sequencing, today announced that it has entered into a five-year [...]

Emblem Announces Settlement With Dissenting Shareholder

08/05/2018 - 22:44

TORONTO, May 08, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV:EMC) (EMC.WT) (" Emblem " or the " Corporation ") announces that it has agreed to issue an aggregate of 482,758 common shares in the capital of Emblem (the “ [...]

Supernus Announces First Quarter 2018 Financial Results and Record Quarterly Revenue

08/05/2018 - 22:40

Total revenue of $90.4 million, a 57% increase over 2017 Net product sales of $89.1 million, a 58% increase over 2017 Operating earnings of $31.4 million, an 87% increase over 2017 Diluted earnings per share (GAAP) of $ [...]

Versartis Reports First Quarter 2018 Financial Results

08/05/2018 - 22:15

MENLO PARK, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Versartis, Inc . (Nasdaq: VSAR ), an endocrine-focused biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2018. “We [...]

Aeterna Zentaris Announces Results of Annual and Special Shareholders’ Meeting

08/05/2018 - 22:15

CHARLESTON, S.C., May 08, 2018 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS ) (TSX: AEZS ) announced today at its annual and special shareholders’ meeting held on May 8, 2018, that the individuals noted below [...]

ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate Update

08/05/2018 - 22:15

End-of-Phase 2 Meeting with the U.S. FDA Scheduled for the Last Week of June to Review Gencaro Phase 2 Data and Future Development Plan WESTMINSTER, Colo., May 08, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: [...]

Alpha Pro Tech, Ltd. Announces Financial Results for the First Quarter Ended March 31, 2018

08/05/2018 - 22:15

Sales for the first quarter of 2018 increased 6.4% to $11.4 million, compared to $10.8 million for the first quarter of 2017 Gross profit for the first quarter of 2018 increased to $4.5 million, up from $4.3 million for [...]

AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates

08/05/2018 - 22:15

Positive Phase 2a Proof-of-Concept Data Reported from ANB020 Trials in Atopic Dermatitis and Peanut Allergy Top-Line Phase 2a Data from ANB020 in Eosinophilic Asthma Expected in the Third Quarter of 2018 SAN DIEGO, May [...]

Precision Optics Corporation Schedules Third Quarter Conference Call

08/05/2018 - 22:15

GARDNER, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (OTCQB:PEYE) (the "Company") announced that it intends to release its financial results for the fiscal year 2018 third quarter ended [...]

Inovalon Reports First Quarter 2018 Results

08/05/2018 - 22:10

First Quarter 2018 Highlights First quarter revenue of $92.8 million First quarter net loss of $16.8 million, resulting in net loss of $0.12 per share First quarter Non-GAAP net loss of $5.0 million, resulting in Non- [...]

EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results

08/05/2018 - 22:10

Completed Substantive Strategic Initiatives to Accelerate Transformation to a Commercial Company Conference Call and Webcast Today, May 8th, at 4:30 p.m. ET WATERTOWN, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- EyePoint [...]

Alder BioPharmaceuticals® Reports First Quarter 2018 Financial and Operating Results

08/05/2018 - 22:07

- 12-Month Data Presented at American Academy of Neurology (AAN) Annual Meeting Demonstrated Eptinezumab Further Reduced Migraine Risk Following Third and Fourth Quarterly Infusions - - Biologics License Application ( [...]

Ovid Therapeutics Reports First Quarter 2018 Financial Results and Corporate Progress

08/05/2018 - 22:06

Data readouts for Ovid’s two lead programs expected in 2018: OV101 STARS trial for adults and adolescents with Angelman syndrome (AS) in third quarter and TAK-935/OV935 Phase 1b/2a trial for adults with rare [...]

Prothena Reports First Quarter 2018 Financial Results and Provides R&D Update

08/05/2018 - 22:05

Net cash used in operating and investing activities was $31.8 million in the first quarter; quarter-end cash and restricted cash position of $433.1 million supports advancement through key milestones of R&D pipeline [...]

Corcept Therapeutics Announces First Quarter 2018 Financial results and Provides Corporate Update

08/05/2018 - 22:05

MENLO PARK, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT ), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic [...]

Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update

08/05/2018 - 22:05

SANTA MONICA, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT ), a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported [...]

miRagen Therapeutics Announces New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis Fungoides

08/05/2018 - 22:05

Treatment resulted in durable improved quality of life Cobomarsen continued to be generally well tolerated at all dose levels evaluated Advancing into a Phase 2 clinical trial in second half of 2018 BOULDER, Colo., May [...]